Advances in the pharmacological treatment of Parkinson's disease: targeting neurotransmitter systems (Q38123275)

scientific article published on 19 July 2013

Language	Label	Description	Also known as
English	Advances in the pharmacological treatment of Parkinson's disease: targeting neurotransmitter systems	scientific article published on 19 July 2013

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

29 August 2017

Advances in the pharmacological treatment of Parkinson's disease: targeting neurotransmitter systems (English)

1 reference

stated in

Europe PubMed Central

29 August 2017

1 reference

1 reference

1 reference

2

1 reference

stated in

Europe PubMed Central

29 August 2017

3

Marc Flajolet

1 reference

stated in

Europe PubMed Central

29 August 2017

Lars Brichta

1

1 reference

stated in

Europe PubMed Central

29 August 2017

19 July 2013

1 reference

stated in

Europe PubMed Central

29 August 2017

Trends in Neurosciences

1 reference

stated in

Europe PubMed Central

29 August 2017

36

1 reference

stated in

Europe PubMed Central

29 August 2017

543-554

1 reference

stated in

Europe PubMed Central

29 August 2017

9

1 reference

stated in

Europe PubMed Central

29 August 2017

Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Homeostatic changes of the endocannabinoid system in Parkinson's disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Evidence of a breakdown of corticostriatal connections in Parkinson's disease.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Dopamine receptors: from structure to function

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Amantadine and other antiglutamate agents: management of Parkinson's disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Non-motor symptoms of Parkinson's disease: diagnosis and management

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Development of dyskinesias in a 5-year trial of ropinirole andL-dopa

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Quantitative light microscopic autoradiographic localization of alpha 2-adrenoceptors in the human brain

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Randomized controlled trial of memantine in dementia associated with Parkinson's disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Distribution of beta‐adrenergic receptor subtypes in human post‐mortem brain: Alterations in limbic regions of schizophrenics

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

A controlled trial of antidepressants in patients with Parkinson disease and depression

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Presynaptic control of serotonin on striatal dopamine function

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

FGF acts as a co-transmitter through adenosine A(2A) receptor to regulate synaptic plasticity

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Synthesis and anticonvulsant activity of a new class of 2-[(arylalky)amino]alkanamide derivatives

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Metabotropic glutamate receptors: physiology, pharmacology, and disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Spared caudal brainstem SERT binding in early Parkinson's disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Serotonin 2A receptors and visual hallucinations in Parkinson disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

The M5 (m5) receptor subtype: fact or fiction?

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Adenosine A(2A) receptors measured with [C]TMSX PET in the striata of Parkinson's disease patients

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

What contributes to quality of life in patients with Parkinson's disease?

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Adrenergic receptors in Alzheimer's disease brain: selective increases in the cerebella of aggressive patients.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Loss of cholinergic neurons in the pedunculopontine nucleus in Parkinson's disease is related to disability of the patients.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Globus pallidus dopamine and Parkinson motor subtypes: clinical and brain biochemical correlation

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005).

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Atrophy of medium spiny I striatal dendrites in advanced Parkinson's disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study)

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Neuronal nicotinic receptors in the human brain

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Evidence for the presence of beta 3-adrenergic receptor mRNA in the human brain

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Muscarinic modulation of striatal function and circuitry.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

alpha 1-Adrenoceptors in the mammalian brain: similar pharmacology but different distribution in rodents and primates

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

The physiology, signaling, and pharmacology of dopamine receptors

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Rivastigmine for dementia associated with Parkinson's disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism?

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway: positive interaction with L-DOPA.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Binding of pramipexole to extrastriatal dopamine D2/D3 receptors in the human brain: a positron emission tomography study using 11C-FLB 457.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Brain serotonin transporter binding in non-depressed patients with Parkinson's disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

A review of central 5-HT receptors and their function

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial).

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson's disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

The neurobiology of slow synaptic transmission

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Depression in Parkinson disease--epidemiology, mechanisms and management.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

The serotonergic system in Parkinson's disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

RGS4-dependent attenuation of M4 autoreceptor function in striatal cholinergic interneurons following dopamine depletion.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Factors impacting on quality of life in Parkinson's disease: results from an international survey.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

The Parkinson's complex: parkinsonism is just the tip of the iceberg

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Frequency-specific and D2 receptor-mediated inhibition of glutamate release by retrograde endocannabinoid signaling

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Metabotropic glutamate receptor type 5 in levodopa-induced motor complications.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Modulation of striatal projection systems by dopamine

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Effects of pedunculopontine nucleus area stimulation on gait disorders in Parkinson's disease.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Heterologous expression of human {alpha}6{beta}4{beta}3{alpha}5 nicotinic acetylcholine receptors: binding properties consistent with their natural expression require quaternary subunit assembly including the {alpha}5 subunit

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Postural instability in Parkinson's disease: the adrenergic hypothesis and the locus coeruleus

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Unilateral pedunculopontine stimulation improves falls in Parkinson's disease.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Dopamine D1, D2, D3 receptors, vesicular monoamine transporter type-2 (VMAT2) and dopamine transporter (DAT) densities in aged human brain

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Identifiers

DOI

10.1016/J.TINS.2013.06.003

1 reference

stated in

Europe PubMed Central

29 August 2017

1 reference

Europe PubMed Central

PubMed ID

23876424

retrieved

29 August 2017

Advances in the pharmacological treatment of Parkinson's disease: targeting neurotransmitter systems (Q38123275)

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Navigation menu

Advances in the pharmacological treatment of Parkinson's disease: targeting neurotransmitter systems (Q38123275)

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Navigation menu

Search